Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Dec 14;3(3):241-51.
doi: 10.1016/j.molmet.2013.12.001. eCollection 2014 Jun.

Action and therapeutic potential of oxyntomodulin

Alessandro Pocai  1
Affiliations
Review

Action and therapeutic potential of oxyntomodulin

Alessandro Pocai. Mol Metab. .

Abstract

Oxyntomodulin (OXM) is a peptide hormone released from the gut in post-prandial state that activates both the glucagon-like peptide-1 receptor (GLP1R) and the glucagon receptor (GCGR) resulting in superior body weight lowering to selective GLP1R agonists. OXM reduces food intake and increases energy expenditure in humans. While activation of the GCGR increases glucose production posing a hyperglycemic risk, the simultaneous activation of the GLP1R counteracts this effect. Acute OXM infusion improves glucose tolerance in T2DM patients making dual agonists of the GCGR and GLP1R new promising treatments for diabetes and obesity with the potential for weight loss and glucose lowering superior to that of GLP1R agonists.

Keywords: Body weight; GLP-1; Glucagon; Glucose metabolism; Oxyntomodulin.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Preproglucagon. Preproglucagon is proteolytically cleaved in a tissue-specific manner. Post-translational processing in the gut and brain by prohormone convertases results in the secretion of GLP-1 and GLP-2, while the glucagon sequence remains in a larger peptide, glicentin or glicentin-related pancreatic peptide (GRPP) and oxyntomodulin. MPGF, major proglucagon fragment.
Figure 2
Figure 2
Effects of oxyntomodulin in humans.
Figure 3
Figure 3
Amino acids sequence alignment of GLP-1, glucagon and glucose-dependent insulinotropic peptide (GIP).
See this image and copyright information in PMC

References

    1. UKPDS U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes. 1995;44:1249–1258. - PubMed
    1. Bray G.A. Medical consequences of obesity. Journal of Clinical Endocrinology and Metabolism. 2004;89:2583–2589. - PubMed
    1. Holst J.J. Gut hormones as pharmaceuticals. From enteroglucagon to GLP-1 and GLP-2. Regulatory Peptides. 2000;93:45–51. - PubMed
    1. Hansen L., Hartmann B., Bisgaard T., Mineo H., Jørgensen P.N., Holst J.J. Somatostatin restrains the secretion of glucagon-like peptide-1 and -2 from isolated perfused porcine ileum. American Journal of Physiology – Endocrinology and Metabolism. 2000;278(6):E1010–E1018. - PubMed
    1. Nauck M.A., Kleine N., Orskov C., Holst J.J., Willms B., Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1993;36:741–744. - PubMed